Trial Profile

A clinical trial evaluating CUE401

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 30 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jun 2025 According to a Cue Biopharma media release, company announced it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA). On the basis of the FDA feedback, the Company, intends to file an IND pending completion of final IND enabling studies.
08 Mar 2023 New trial record
01 Mar 2023 According to a Cue Biopharma media release, the company will take part in two investor healthcare conferences in March, the Cowen 43rd Annual Health Care Conference being held in Boston, Massachusetts March 6-8, 2023, and the Oppenheimer 33rd Annual Healthcare Conference being held virtually March 13-15, 2023; the company will also discuss their newly established partnership with Ono Pharmaceutical to help advance Cue Biopharmas lead autoimmune disease asset, CUE-401, toward the clinic.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com